CEP18770 is primarily utilized in the field of cancer research due to its role as a proteasome inhibitor. It has shown potential in preclinical studies for the treatment of various types of cancers, particularly multiple myeloma. The compound works by inhibiting the activity of the proteasome, a complex that degrades damaged or unnecessary proteins in cells. By blocking this process, CEP18770 leads to the accumulation of proteins that can trigger cancer cell death. This mechanism makes it a promising candidate for developing targeted cancer therapies. Researchers are also exploring its effectiveness in combination with other anticancer agents to enhance treatment outcomes. Additionally, its application extends to studying cellular processes related to protein degradation and stress responses, providing insights into broader biological mechanisms.